The non-cell-permeable HSP90 inhibitor HS30 significantly inhibited eHSP90α and LRP1 colocalization, which was significantly increased in patients with moderate and severe IPF. This evidence concerns the gene HSP90AB1 and idiopathic pulmonary fibrosis.